Cargando...
Valproic acid disrupts the oscillatory expression of core circadian rhythm transcription factors
Valproic acid (VPA) is a well-established therapeutic used in treatment of seizure and mood disorders as well as migraines and a known hepatotoxicant. About 50% of VPA users experience metabolic disruptions, including weight gain, hyperlipidemia, and hyperinsulinemia, among others. Several of these...
Gardado en:
| Publicado en: | Toxicol Appl Pharmacol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6503860/ https://ncbi.nlm.nih.gov/pubmed/29229235 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.taap.2017.12.005 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|